🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the battle against drug-resistant strains of the infection, according to scientists.

An International Public Health Issue

The sexually transmitted infection are increasing worldwide, with data suggesting over 82 million new cases annually. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, the spread of superbugs and the very limited treatment choices currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is employed against UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This approval represents a huge turning point in the management of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Results and Global Access

As per results released by a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses two antibiotics. The trial involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the rights to register and commercialise the drug in numerous developing nations.

Clinicians on the front lines have expressed optimism. Having a single-dose, oral treatment like this is hailed as a "game-changer" for managing the epidemic. This is deemed crucial to lessen the impact of the illness for individuals and to prevent the spread of untreatable gonorrhoea around the world.